Abstract |
We used the partial sciatic nerve ligation (PSL) model of Seltzer to assess thermal hyperalgesia after administration of Prosaptide 14-mer, TX14(A). At a dose of 200 microg/kg in Wistar rats, subcutaneous delivery of TX14(A) reversed thermal hyperalgesia at 3 and 24 h. Values declined at 48 h and returned to baseline at 72 h. A dosing study of TX(14)A gave a dependent response with 100 microg/kg having a similar potency to the 200 microg/kg study with 50 and 10 microg/kg responding somewhat lower. When TX(14)A was administered every fourth day for 12 days at 100 microg/kg, 24 h post injection values returned to baseline each time. Our results suggest that Prosaptide may have potential for therapeutic use in neuropathic pain syndromes in humans.
|
Authors | D A Otero, B Conrad, J S O'Brien |
Journal | Neuroscience letters
(Neurosci Lett)
Vol. 270
Issue 1
Pg. 29-32
(Jul 23 1999)
ISSN: 0304-3940 [Print] Ireland |
PMID | 10454138
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Nerve Growth Factors
- prosaptide
|
Topics |
- Amino Acid Sequence
- Animals
- Dose-Response Relationship, Drug
- Hot Temperature
- Hyperalgesia
(physiopathology, prevention & control, therapy)
- Molecular Sequence Data
- Nerve Growth Factors
(chemistry, therapeutic use)
- Rats
- Rats, Wistar
- Sciatic Nerve
(physiology, physiopathology)
- Time Factors
|